Document rp6g6Z1rOyXOGg3dG3EGqNDwr

To: Gagen, Stuart Z SHLOIL-SHOIL-SHS <stuart.cagen@shell.com>; 'Russell White' <whiter@api.org>; 'michael.g.bird@exxonmobil.com' <michael.g.bird@exxonmobil.com> From: Tsai, Shan P SHLOIL-SHS </O=SHE LUOU=MSXSOGIGN=RE GI PI ENTS/GN=ST196949> Gc: 'Bruce Jarnot' <jarnotb@api.org> Bcc: Received Date: 2006-11-15 15:38:48 GMT Subject: RE: Shanghai Health Study - new budget estimate I am on business this week and vacation next week. Will try to call Dr. Fu next week. Shan -----Original Message----From: Gagen, Stuart Z SHLOIL-SHOIL-SHS Sent: Tuesday, November 14, 2006 12: 15 AM To: 'Russell White'; michael.g.bird@exxonmobil.com; Tsai, Shan P SHLOIL-SHS Gc: Bruce Jarnot Subject: RE: Shanghai Health Study - new budget estimate Russ: Have you contacted Dr. Fu for an estimate based on the assumption of case accrual until the end of 2007 ? think Shan Tsai is the contact from the technical committee. Shan: a possible request for you to call Dr. Fu as per the response from Russ I have not yet heard from Otto. Thanks Stuart Stuart Gagen, Ph.D. Senior Toxicologist Shell Health Services One Shell Plaza 910 Louisiana Street Houston, Texas 77002 Telephone: 1-713-241-1407 Fax: 1-713-241-3325 Mobile: 1-832-646-3987 email: stuart.cagen@shell.com -----Original Message----From: Russell White [mailto:whiter@api.org] Sent: Monday, November 13, 20062:57 PM To: michael.g.bird@exxonmobil.com Gc: Gagen, Stuart Z SHLOIL-SHOIL-SHS; Bruce Jarnot Subject: RE: Shanghai Health Study - new budget estimate SH ELL-MCCLU RG-OS4962 API has a separate with Fudan for support of the case-control study. I'm putting together a spreadsheet that will include the new data and estimates for all contracts. -----Original Message----From: michael.g.bird@exxonmobil.com [mailto:michael.g.bird@exxonmobil.com] Sent: Monday, November 13, 2006 3:49 PM To: Russell White Cc: stuart.cagen@shell.com Subject: Re: Shanghai Health Study - new budget estimate Russ, I know that Stuart is working Otto Wong's needs, but I believe there was mention of some separate contract or support for Dr Fu? If so is that part of Otto's contract or a separate EA activity? Just want to make sure that everything is covered. Michael Michael G. Bird, PhD., DABT Toxicology & Environmental Sciences Division, ExxonMobil Biomedical Sciences, Inc. 1545 Route 22 East P.O. Box 971 Annandale, New Jersey 08801-0971 tel: 9087301060 fax: 908 730 1199 Email: michael.g.bird@exxonmmobil.com This document and all information contained within this electronic message may be privileged, confidential and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited. "Russell White" <whiter@api.or To g> <BenzConsort-OC@listserve.api.org>, <BenzConsort-TC@listserve.api.org> cc 11/13/0602:57 PM SH ELL-MCCLU RG-OS4963 Subject Shanghai Health Study - new budget estimate Greetings, Some OC members have asked for an estimate of individual company costs base on Dr. Irons new budget estimates. Using the eleven shares formula (XOM and BP have 3 shares, Chevron and Shell have 2 shares, and ConocoPhillips has 1 share); Finish study - $5,759,864 1 share $523,624 2 shares $1 ,047,248 3 shares $1 ,570,872 Finish study and transition lab - $6,999,864 1 share $636,351 2 shares $1 ,272,703 3 shares $1 ,909,054 Finish study, transition lab, and publish results - $7,599,864 1 share $690,897 2 shares $1 ,381 ,793 3 shares $2,072,690 SH ELL-MCCLU RG-OS4964